RATIO-LAMOTRIGINE TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

LAMOTRIGINE

Pieejams no:

TEVA CANADA LIMITED

ATĶ kods:

N03AX09

SNN (starptautisko nepatentēto nosaukumu):

LAMOTRIGINE

Deva:

100MG

Zāļu forma:

TABLET

Kompozīcija:

LAMOTRIGINE 100MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Ārstniecības joma:

MISCELLANEOUS ANTICONVULSANTS

Produktu pārskats:

Active ingredient group (AIG) number: 0127134001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2016-12-05

Produkta apraksts

PRODUCT MONOGRAPH
RATIO-LAMOTRIGINE
(lamotrigine)
25, 100 and 150 mg Tablets
Antiepileptic
Teva Canada Limited
Date of Revision:
30 Novopharm Court
November 6, 2014
Toronto, Ontario
Canada
M1B 2K9
Control No.: 178540
2
PRODUCT MONOGRAPH
DO NOT EXCEED THE RECOMMENDED INITIAL DOSE AND SUBSEQUENT DOSE
ESCALATIONS OF RATIO-
LAMOTRIGINE. MORE RAPID INITIAL TITRATION HAS BEEN ASSOCIATED WITH AN
INCREASED INCIDENCE
OF SERIOUS DERMATOLOGICAL REACTIONS (SEE WARNINGS).
RATIO-LAMOTRIGINE
lamotrigine
(25, 100 and 150 mg Tablets)
ANTIEPILEPTIC
ACTION AND CLINICAL PHARMACOLOGY
Lamotrigine is a drug of the phenyltriazine class chemically unrelated
to existing antiepileptic drugs
(AEDs).
Lamotrigine is thought to act at voltage-sensitive sodium channels to
stabilize neuronal membranes
and inhibit the release of excitatory amino acid neurotransmitters
(e.g. glutamate, aspartate) that are
thought to play a role in the generation and spread of epileptic
seizures.
CLINICAL TRIALS
In adult placebo-controlled clinical studies, lamotrigine has been
shown to be effective in reducing
seizure frequency and the number of days with seizures when added to
existing antiepileptic drug
therapy in adult patients with partial seizures,
with or without generalized tonic-clonic seizures, that
are not satisfactorily controlled.
The effectiveness of lamotrigine adjunctive therapy has also been
shown in pediatric and adult
patients with Lennox-Gastaut syndrome. A significant reduction in
major motor seizures, drop
attacks, and tonic-clonic seizures were seen following lamotrigine
treatment compared with placebo
treated patients. Improvements in cognitive skills (speech, nonverbal
communication, alertness,
attention, intellectual capacity), behaviour, and fine coordination
have been seen with lamotrigine
treatment in these patients.
Studies have also been conducted using lamotrigine monotherapy in
adult patients (n = 443) newly
diagnosed with epilepsy (partial seizures, with or without secondary
generalization or primary
generalized tonic clonic). Resu